Q3 Korean Biotech Roundup: Eyes On Orum's IPO Plan
HLB Resubmits HCC Combo In US
Recent major developments in the Korean biotech sector include Orum Therapeutics’ IPO plan and HLB’s US resubmission for the approval of rivoceranib in combination with camrelizumab for first-line liver cancer.
